Changeflow GovPing Healthcare & Life Sciences Stabilized trimeric class I fusion proteins pat...
Routine Notice Added Final

Stabilized trimeric class I fusion proteins patent application

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO has published a patent application (US20260085096A1) for stabilized trimeric class I fusion proteins. The application details specific mutations in the HR2 domain to enhance protein stability. This is a routine publication of a new patent application.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a publication of a patent application filed by inventors Johannes Petrus Maria LANGEDIJK, Mark Johannes Gerardus BAKKERS, Annemart KOORNNEEF, and Jaroslaw JURASZEK. The application, titled 'Stabilized trimeric class I fusion proteins,' describes novel fusion proteins with stabilizing mutations in the HR2 domain, potentially impacting the development of new therapeutic proteins.

As this is a patent application publication, there are no immediate compliance obligations for regulated entities. However, companies in the pharmaceutical and biotechnology sectors should monitor this application and related patents for potential future intellectual property considerations and competitive landscape analysis. The application was filed on September 15, 2023, and published on March 26, 2026.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

STABILIZED TRIMERIC CLASS I FUSION PROTEINS

Application US20260085096A1 Kind: A1 Mar 26, 2026

Inventors

Johannes Petrus Maria LANGEDIJK, Mark Johannes Gerardus BAKKERS, Annemart KOORNNEEF, Jaroslaw JURASZEK

Abstract

The present invention relates to trimeric class I fusion proteins, in particular to class I fusion proteins, comprising at least one stabilizing mutation in the HR2 domain, and to fragments thereof.

CPC Classifications

C07K 14/005 C12N 15/86 C12N 2710/10343 C12N 2760/18222 C12N 2760/18622 C12N 2770/20022

Filing Date

2023-09-15

Application No.

19113685

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 26th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085096A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Biotechnology Research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11
Topics
Biotechnology Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!